D-0509-2023 Class II Ongoing
FDA drug recall D-0509-2023 was initiated by Direct Rx on Mar 22, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer. The recall status is ongoing. Affected quantity: 9 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 12, 2023
- Initiation Date
- Mar 22, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 9 bottles
Product description
Alprazolam C-IV, 2 mg, 60 Tabs per bottle, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534, NDC 72189-121-60.
Reason for recall
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
Distribution pattern
Nationwide in the USA
Code information
Lots: 03FE2319 Exp. 2/28/25, 13MY2217 Exp. 5/31/23
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0509-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026